ALX ONCOLOGY HOLDINGS INC Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
ALX ONCOLOGY HOLDINGS INC (ALXO) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $168.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-08-06
- ALX ONCOLOGY HOLDINGS INC right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2022-12-31 was -$71.00K.
- ALX ONCOLOGY HOLDINGS INC right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2022-09-30 was $0.00.
- ALX ONCOLOGY HOLDINGS INC right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2022-06-30 was $1.26M.
- ALX ONCOLOGY HOLDINGS INC right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2022-03-31 was $3.42M.
- ALX ONCOLOGY HOLDINGS INC right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $4.61M, a 159.16% increase from fiscal 2021.
- ALX ONCOLOGY HOLDINGS INC right-of-use asset obtained in exchange for operating lease liability for fiscal 2021 was $1.78M.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | $168.00K 10-Q · filed 2026-08-06 | |||
| 2022-12-31 | -$71.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | -$71.00K derived: sum of 2 quarters · filed 2025-03-06 | $1.19M derived: sum of 3 quarters · filed 2025-03-06 | $4.61M 10-K · filed 2025-03-06 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $1.26M derived: sum of 2 quarters · filed 2023-11-13 | $4.68M 10-Q · filed 2023-11-13 | $4.65M derived: sum of 4 quarters · filed 2024-03-07 |
| 2022-06-30 | $1.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $4.68M 10-Q · filed 2023-08-10 | $4.65M derived: sum of 3 quarters · filed 2024-03-07 | $4.65M derived: sum of 4 quarters · filed 2024-03-07 |
| 2022-03-31 | $3.42M 10-Q · filed 2023-05-11 | $3.39M derived: sum of 2 quarters · filed 2024-03-07 | $3.39M derived: sum of 3 quarters · filed 2024-03-07 | |
| 2021-12-31 | -$32.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | -$32.00K derived: sum of 2 quarters · filed 2024-03-07 | $1.78M 10-K · filed 2024-03-07 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $1.81M 10-Q · filed 2022-11-08 | ||
| 2021-06-30 | $1.81M 10-Q · filed 2022-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |